203 related articles for article (PubMed ID: 31038055)
1. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
3. The role of glutaminase in cancer.
Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
[TBL] [Abstract][Full Text] [Related]
4. Glutaminases regulate glutathione and oxidative stress in cancer.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Márquez J
Arch Toxicol; 2020 Aug; 94(8):2603-2623. PubMed ID: 32681190
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer.
Matés JM; Segura JA; Martín-Rufián M; Campos-Sandoval JA; Alonso FJ; Márquez J
Curr Mol Med; 2013 May; 13(4):514-34. PubMed ID: 22934847
[TBL] [Abstract][Full Text] [Related]
6. Glutaminases in brain: Multiple isoforms for many purposes.
Campos-Sandoval JA; Martín-Rufián M; Cardona C; Lobo C; Peñalver A; Márquez J
Neurochem Int; 2015 Sep; 88():1-5. PubMed ID: 25837287
[TBL] [Abstract][Full Text] [Related]
7. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Matés JM; Di Paola FJ; Campos-Sandoval JA; Mazurek S; Márquez J
Semin Cell Dev Biol; 2020 Feb; 98():34-43. PubMed ID: 31100352
[TBL] [Abstract][Full Text] [Related]
9. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
10. Two Faces of Glutaminase GLS2 in Carcinogenesis.
Buczkowska J; Szeliga M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067269
[TBL] [Abstract][Full Text] [Related]
11. Structure and activation mechanism of the human liver-type glutaminase GLS2.
Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation.
López de la Oliva AR; Campos-Sandoval JA; Gómez-García MC; Cardona C; Martín-Rufián M; Sialana FJ; Castilla L; Bae N; Lobo C; Peñalver A; García-Frutos M; Carro D; Enrique V; Paz JC; Mirmira RG; Gutiérrez A; Alonso FJ; Segura JA; Matés JM; Lubec G; Márquez J
Sci Rep; 2020 Feb; 10(1):2259. PubMed ID: 32042057
[TBL] [Abstract][Full Text] [Related]
13. Glutaminase inhibition as potential cancer therapeutics: current status and future applications.
Cyriac R; Lee K
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290911. PubMed ID: 38078371
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of glutaminase and glutamine synthetase in cancer.
Matés JM; Campos-Sandoval JA; Santos-Jiménez JL; Márquez J
Cancer Lett; 2019 Dec; 467():29-39. PubMed ID: 31574293
[TBL] [Abstract][Full Text] [Related]
15. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
16. Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.
de Los Santos-Jiménez J; Campos-Sandoval JA; Márquez-Torres C; Urbano-Polo N; Brøndegaard D; Martín-Rufián M; Lobo C; Peñalver A; Gómez-García MC; Martín-Campos J; Cardona C; Castilla L; da Costa Souza F; Cheng T; Segura JA; Alonso FJ; Curi R; Colquhoun A; DeBerardinis RJ; Márquez J; Matés JM
J Biomed Sci; 2021 Feb; 28(1):14. PubMed ID: 33610185
[TBL] [Abstract][Full Text] [Related]
17. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer.
Saha SK; Islam SMR; Abdullah-Al-Wadud M; Islam S; Ali F; Park KS
J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30871151
[TBL] [Abstract][Full Text] [Related]
18. Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
Szeliga M; Albrecht J
Neurochem Int; 2015 Sep; 88():6-9. PubMed ID: 25529918
[TBL] [Abstract][Full Text] [Related]
19. Expression of Gls and Gls2 glutaminase isoforms in astrocytes.
Cardona C; Sánchez-Mejías E; Dávila JC; Martín-Rufián M; Campos-Sandoval JA; Vitorica J; Alonso FJ; Matés JM; Segura JA; Norenberg MD; Rama Rao KV; Jayakumar AR; Gutiérrez A; Márquez J
Glia; 2015 Mar; 63(3):365-82. PubMed ID: 25297978
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.
Lukey MJ; Greene KS; Erickson JW; Wilson KF; Cerione RA
Nat Commun; 2016 Apr; 7():11321. PubMed ID: 27089238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
